

October 24, 2022



Stevanato Group to Report Third Quarter 2022 Financial Results on November 8, 2022

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2022 on Tuesday, November 8, 2022, at 6:30 a.m. (ET).

Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 8, 2022 to discuss financial results for the third quarter. During the call, management will refer to a slide presentation which will be available at 6:30 a.m. (ET) on the day of the call on the “Financial Results” page under the Company’s Investor Relations section of its website.

Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link:

<http://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=4544003&linkSecurityString=514976446>

Webcast: A live, listen-only webcast of the call will be available at the following link:

<https://87399.choruscall.eu/links/stevanato221108.html>

Dial in: Those who are unable to pre-register may dial in by calling:

Italy:	+39 02 802 09 11
UK:	+44 1 212 818004
USA:	+1 718 705 8796
USA Toll Free:	+1 855 265 6958

Replay:

The webcast will be archived for three months on the Company’s Investor Relations section of its website at:

<https://ir.stevanatogroup.com/financial-results>.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products,

processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. For more information, please visit www.stevanatogroup.com.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20221024005962/en/>

Investor Relations

Lisa Miles

lisa.miles@stevanatogroup.com

Media

media@stevanatogroup.com

Source: Stevanato Group S.p.A.